Skip to content

Chikungunya Glycoprotein E1 Antigen BA148R2



  • Virion/Serion Immunologics Antigen for research use (RUO)
  • Chikungunya Glycoprotein E1 Antigen, recombinant
  • Suitable for detection of IgA, IgG & IgM antibodies in ELISA
  • Lot specific concentration, specified in mg/mL
  • 1 mg
Weight1 lbs
Dimensions9 × 5 × 2 in

Chikungunya Glycoprotein E1

species reactivity

Chikungunya virus



assay type

Indirect & quantitative

available size

1 mg

Chikungunya Glycoprotein E1 Antigen BA148R2

Research area
Infectious Disease
Store -65°C or below. Avoid repeated freeze-thaw cycles. Avoid repeated freeze-thaw cycles.
Associated products
Chikungunya Glycoprotein E2 Antigen (BA148R1)
Chikungunya Glycoprotein E1 Antigen (BA148R2)
Chikungunya Glycoprotein E1 (A226V) Antigen (BA148R3)
Chikungunya Virus Human IgG Assay Control (BC148G)
Chikungunya Virus Human IgM Assay Control (BC148M)
Chikungunya Virus IgG ELISA Kit (ESR148G)
Chikungunya Virus IgM ELISA Kit (ESR148M)
target relevance
Chikungunya Virus
Structure and strains
Chikungunya is an infection caused by the Chikungunya virus (CHIKV). The disease was first identified in 1952 in Tanzania and named based on the Kimakonde words for "to become contorted". Symptoms include fever and joint pain. These typically occur two to twelve days after exposure. Other symptoms may include headache, muscle pain, joint swelling, and a rash. Symptoms usually improve within a week; however, occasionally the joint pain may last for months or years. The risk of death is around 1 in 1,000. The very young, old, and those with other health problems are at risk of more severe disease.
The chikungunya virus is a member of the alphavirus genus. It is also classified as arbovirus due to vector-dependent transmission by mosquitos. The enveloped virus carries structural glycoproteins E1-E3 that are particular immunogenic. Within the viral capsid several non-structure proteins and a ss-(+)-RNA genome are embedded.

The virus is the causative agent of chikungunya fever that is characterized by fever, joint pain and joint swelling, rash, and unspecific flu-like symptoms. The symptoms usually appear within a period of one to two weeks but mainly appear during the first week post infection. The disease is characterized by a biphasic course with an initial stage with high virus load (5-7 days) and a convalescent stage without viremia. A chronic course of disease that goes along with severe joint pain might occur. In rare cases neurological disorders like Guillain-Barre syndrome and meningoencephalitis, also with lethal courses, were described.
Detection and diagnosis
The diagnosis is mainly based on direct pathogen detection or serological methods. Within the early phases virus detection by RT-PCR is the method of choice. After the onset of immune responses viremia will drop leading to reduced sensitivity of direct detection methods. Achieving this stage demonstration of specific antibodies should be used for diagnosis. Due to persistence of IgG and to lesser extent IgM antibody serology allows for retrospective evaluation.



Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.



relevant to this product
BA148R2 protocol


Product data sheet


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.